Investors cheered by Pacific Edge news
An optimistic update from cancer diagnostics company Pacific Edge gave its shares a boost after a trading halt this morning interrupted investor gloom over bad news from the US.
In a statement to the NZX, Pacific Edge said it had been notified its Triage Plus product could receive a price of US$1018
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Business Review
15 hours ago
- National Business Review
Aussie PE firm seeks ComCom clearance to acquire Metroglass
Australian private equity firm Crescent Capital Partners is seeking regulatory approval to acquire NZX-listed Metro Performance Glass despite the company rejecting its previous offer. The Commerce Commission this morning said it had received an application from Viridian NZ BidCo Ltd, an entity which
Otago Daily Times
2 days ago
- Otago Daily Times
Pacific Edge raises $16m in share sale
Pacific Edge has raised $16 million in new equity in a placement of new ordinary shares — $1m more than it sought — after accepting over-subscriptions. On Friday, the cancer diagnostics company announced a $20m capital raise, saying it was about ensuring it had the cash reserves to capitalise on recent clinical and commercial milestones, grow in non-Medicare channels in the United States and regain Medicare coverage of its tests. It comprised a placement of $15m of new ordinary shares offered to selected investors and an offer of $5m of new shares to retail investors, by way of a share-purchase plan. The share issue was priced at $0.10 per share. Yesterday, the company said the placement — which was well-supported by existing shareholders — was completed on Friday and was subject to shareholder approval. It was now targeting the opening of a $5m offer to eligible retail investors at the same per share offer price in July or early August, with the ability to accept oversubscriptions. In a statement to the NZX, chairman Chris Gallaher said the company was delighted with the investor support it had received. The inclusion of Cxbladder in the American Urological Association's (AUA) new microhematuria guideline in February was significant and had allowed the company to view the non-coverage determination differently. "We are leveraging the important AUA guideline to build on the commercial momentum we have already established, including our plans to regain Medicare coverage," he said. Medicare coverage of the company's tests ceased after the Local Coverage Determination (LCD) became effective on April 24. In a note on Pacific Edge's FY25 financial result also released on Friday, Forsyth Barr analysts described it as "relatively uneventful". Revenue was consistent with the firm's expectations and costs were slightly higher than expected. Despite Pacific Edge being adamant for some time it had sufficient cash resources to navigate the LCD uncertainty, the analysts were not surprised by the capital raise. It was the company's 11th equity raise since 2003 — cumulative raises totalled more than $260m — which would take its share count to more than 1billion from just under 10million in 2004. Post-raise, its cash balance would be about $38m ($22.6 million at FY25) and the analysts estimated that was 16 to 18 months of cash on hand. "While this is a supportive lifeline, even in the event of [Medicare] recoverage, we aren't convinced this is the last of PEB's raises," they said. s
Scoop
2 days ago
- Scoop
Blackpearl Group Hits $12.5M ARR, Targets $50M Leveraging Multi-product Innovation
Press Release – Blackpearl Group As the AI landscape continues to shift, Blackpearl is not just chasing the future – it's actively building it. The AI opportunity is here and our platform has been purpose-built to capture it.' Blackpearl Group Limited (NZX: BPG) has announced its results for the year ended 31 March 2025, recording an astounding 70% increase in Annual Recurring Revenue (ARR) and sharp rise in average revenue per user, underpinned by a multi-product innovation strategy. With $12.5m in ARR, Blackpearl is positioning not just for $20m ARR but to build toward $50m and beyond. 'Last year, we committed to setting ourselves up for the next stage of growth. We have the potential to be a billion-dollar company and we're creating a portfolio of solutions that balance high-risk innovation with consistent, long-term performance. We're innovating and executing at a pace that's hard for anyone to keep up with,' commented Nick Lissette, Chief Executive Officer. Building for the next stage of growth Lissette believes Blackpearl's success is rooted in an ability to innovate at pace on an ongoing basis. 'Last year, we told investors we would invest in the next stage of growth and we've proven this with the launch of Bebop, an AI-powered sales intelligence tool developed in a single quarter and the most successful beta in the company's history,' he explains. 'We're targeting the SME market in the US with AI-powered solutions that deliver measurable growth. With Pearl Diver firmly embedded and Bebop now live, the next phase of Blackearl's trajectory is dominance,' believes Lissette. Innovation powered by execution Importantly, this innovation has been strengthened by disciplined execution. 'At the same time, we've focused on scaling our core data infrastructure and transitioning to high-value enterprise customers. This has been a powerful multiplier of sustainable growth as we position ourselves for what's next,' comments Chief Financial Officer Karen Cargill. Pearl Engine, the core platform behind Blackpearl's products, has scaled by 210x over the past year and now processes 21 billion rows of data per day. What's more, average revenue per user (ARPU) reached $17.5k, marking a sharp 53% increase over the past six months and subscription revenue is up 91% from FY24. Highlights • $12.5m ARR, up 70% from $7.4m as at 31 March 2024 • $7.7m subscription revenue, up 91% from $4.1m in FY24 • $17.5k ARPU, up 53% over the last 6 months • 68% gross margin, reflecting continued platform efficiency • 17% of revenue from top 10 customers, up from 10% as at 31 March 2024 • Pearl Diver reached ~$10m ARR, only eight quarters after its full launch • Raised $12.5m in growth capital • Officially launched Bebop, following the most successful beta in the company's history Building the future 'As the AI landscape continues to shift, Blackpearl is not just chasing the future – it's actively building it. The AI opportunity is here and our platform has been purpose-built to capture it. We're positioned to lead AI-powered sales and marketing solutions for the US SME market and we're entering FY26 with clear momentum, a disciplined growth strategy and a compelling value proposition for investors,' concludes Lissette.
